H.C. Wainwright Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
H.C. Wainwright initiates coverage on Biohaven Pharmaceutical Holding (NYSE: BHVN) with a Buy rating.
Shares of Biohaven Pharmaceutical Holding closed at $86.99 yesterday.
You May Also Be Interested In
- Credit Suisse Assumes Airbus SE (AIR:FP) (EADSY) at Outperform
- Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
- UPDATE: Needham & Company Starts Ping Identity Holding Corp. (PING) at Hold
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!